| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2020 |
SC 13G/A
| FMR LLC reports a 13.9% stake in SIENNA BIOPHARMACEUTICALS INC |
| 02/05/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/17/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/11/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 12/11/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
8-K
| Quarterly results |
| 11/15/2019 |
8-K
| Quarterly results |
| 11/14/2019 |
GN
| Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice |
| 11/12/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 10/17/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/23/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 09/17/2019 |
8-K
| Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation unde... |
| 08/08/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 06/20/2019 |
GN
| Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference |
| 06/10/2019 |
GN
| Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology |
| 06/03/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/21/2019 |
GN
| Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe |
| 05/14/2019 |
GN
| Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis |
| 05/09/2019 |
GN
| Sienna Biopharmaceuticals to Present at BAML Health Care Conference |
| 05/08/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 05/08/2019 |
8-K
| Quarterly results |
| 04/11/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/11/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/21/2019 |
GN
| Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations |
| 03/14/2019 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/14/2019 |
8-K
| Quarterly results |
| 03/14/2019 |
GN
| Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results |
| 03/06/2019 |
SC 13D
| ARCH Venture Fund VIII, L.P. reports a 19.9% stake in Sienna Biopharmaceuticals, Inc. |
|